- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 24.08. | Spruce's successful FDA talks plant seeds for Q4 filing of ultra-rare disease drug | ||
| 24.08. | Regenxbio gene therapy refiling plan derailed by FDA hold over spine MRI findings | ||
| 24.08. | Roche pens $2.5B pact for Hanmi's clinical-stage obesity drug targeting less-explored mechanism | ||
| 21.08. | Werewolf Therapeutics transforms into Ambros Therapeutics via reverse merger to support phase 3 push for rare disease drug | ||
| 20.08. | Lilly pens deal with Gateway Labs alumni Amplitude for RNA vaccine platform for infectious disease | ||
| 20.08. | Merck-Moderna cancer vaccine win spurs stock jump, speculation of Keytruda-like impact | ||
| 19.08. | Trump looks set to tap White House aide Heidi Overton as next FDA commissioner | ||
| 19.08. | Tolerance Bio jumps into phase 2 with $260M deal for thymus-targeting fusion protein | ||
| 18.08. | Merck and Sarah Cannon team up to boost oncology trial efficiency | ||
| 18.08. | Kolon TissueGene shrinks workforce after pivotal osteoarthritis trial miss | ||
| 18.08. | BioMarin bulks up bone unit with $275M Alesta buyout to challenge AstraZeneca | ||
| 17.08. | Regeneron ends eye disease trial for anti-CD3 antibody following safety review | ||
| 17.08. | Merck KGaA lays off 20 staffers in latest blow to US research team | ||
| 17.08. | Slate Medicines uses Fulcrum Therapeutics to vault onto Nasdaq with $245M financing for migraine trials | ||
| 17.08. | Evaxion scraps solid tumor vaccine to focus on Duke-partnered brain cancer candidate | ||
| 17.08. | Lilly pens $370M deal with OmniAb for ion channel collab, but details remain vague | ||
| 17.08. | AstraZeneca ends phase 3 lung cancer trial after bispecific falls short versus Keytruda | ||
| 14.08. | Skye and Redx form new entity with $125M to advance fibrosis assets | ||
| 14.08. | 'We're not afraid of competition': BioCryst CEO sets out strategy after scrapping internal discovery | ||
| 14.08. | Capricor soars on plan to amend DMD filing after adcomm setback | ||
| 14.08. | MapLight dims preclinical programs to make phase 3-ready schizophrenia drug shine brighter | ||
| 13.08. | PDS halts work on phase 3 cancer therapy to focus on colorectal contender | ||
| 13.08. | PTC's $211M bid wins Sangamo auction, teeing up 'special opportunity' to enter Fabry market | ||
| 13.08. | Cullinan tees up J&J fight-and $100M payday-as Taiho-partnered drug hits phase 3 cancer goal | ||
| 13.08. | Zealand sells its rights to Takeda's blood cancer drug for $100M ahead of FDA approval decision |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.